Maze Therapeutics, Inc. (MAZE) Stock Research

Maze Therapeutics, Inc.

· MAZE

Dashboard

Financials

Ratios

Valuation

Statistics

1.501 B

+0.59%

Over a week ago

Maze Therapeutics initiated with bullish view at Citi, here's why

MAZE

Sep 23, 5:17 AM

Truist sees 'significant positive readthrough' for Maze from Vertex data

Sep 22, 10:29 AM

Maze jumps 25% to $27.99 after Vertex kidney disease data

Sep 22, 10:23 AM

Maze Therapeutics reports Q2 EPS (76c), consensus (70c)

MAZE

Aug 11, 4:10 PM

Maze Therapeutics reports Q1 EPS (45c), consensus (63c)

MAZE

May 12, 4:14 PM

Maze Therapeutics priced offering of 5.54M shares of common stock at $23.50

MAZE

Apr 22, 7:53 AM

Maze Therapeutics price target lowered by $4 at Truist, here's why

MAZE

Apr 14, 7:12 AM

Maze Therapeutics price target raised by $6 at JPMorgan, here's why

MAZE

Mar 31, 6:42 AM

What You Missed On Wall Street On Wednesday

+26

Mar 25, 4:27 PM

Maze Therapeutics falls -29.8%

MAZE

Mar 25, 12:00 PM

Midday Fly By: Merck to acquire Terns, Arm CPU launch applauded

+24

Mar 25, 11:59 AM

Maze Therapeutics share sell-off an 'overreaction,' says Raymond James

Mar 25, 11:32 AM

Maze Therapeutics falls -33.2%

MAZE

Mar 25, 10:00 AM

Leerink remains bullish on Maze, says Vertex comparison 'apples to oranges'

Mar 25, 9:32 AM

Maze Therapeutics price target raised by $50 at H.C. Wainwright, here's why

MAZE

Mar 25, 9:23 AM

Maze Therapeutics up 15% at $56.43 after Q4 results and MZE829 trial data

MAZE

Mar 25, 8:00 AM

Maze Therapeutics reports Q4 EPS (65c), consensus (78c)

MAZE

Mar 25, 8:00 AM

Maze Therapeutics announces positive topline data from Phase 2 HORIZON Trial

MAZE

Mar 25, 7:59 AM

Block upgraded, Starbucks downgraded: Wall Street's top analyst calls

+12

Mar 18, 9:34 AM

Maze Therapeutics initiated with bullish view at Truist, here's why

MAZE

Mar 17, 4:11 PM

Maze Therapeutics price target raised by $15 at Wedbush, here's why

MAZE

Mar 16, 7:58 AM

Qualcomm downgraded, Rivian upgraded: Wall Street's top analyst calls

+12

Mar 10, 9:34 AM

Maze Therapeutics initiated with bullish view at Mizuho, here's why

MAZE

Mar 10, 4:41 AM

Maze Therapeutics price target raised by $12 at Guggenheim, here's why

MAZE

Mar 4, 7:18 AM

Maze Therapeutics files automatic mixed securities shelf

MAZE

Feb 4, 5:20 PM

Charts

Over a week ago

Maze Therapeutics initiated with bullish view at Citi, here's why

MAZE

Sep 23, 5:17 AM

Truist sees 'significant positive readthrough' for Maze from Vertex data

Sep 22, 10:29 AM

Maze jumps 25% to $27.99 after Vertex kidney disease data

Sep 22, 10:23 AM

Maze Therapeutics reports Q2 EPS (76c), consensus (70c)

MAZE

Aug 11, 4:10 PM

Maze Therapeutics reports Q1 EPS (45c), consensus (63c)

MAZE

May 12, 4:14 PM

Maze Therapeutics priced offering of 5.54M shares of common stock at $23.50

MAZE

Apr 22, 7:53 AM

Maze Therapeutics price target lowered by $4 at Truist, here's why

MAZE

Apr 14, 7:12 AM

Maze Therapeutics price target raised by $6 at JPMorgan, here's why

MAZE

Mar 31, 6:42 AM

What You Missed On Wall Street On Wednesday

+26

Mar 25, 4:27 PM

Maze Therapeutics falls -29.8%

MAZE

Mar 25, 12:00 PM

Midday Fly By: Merck to acquire Terns, Arm CPU launch applauded

+24

Mar 25, 11:59 AM

Maze Therapeutics share sell-off an 'overreaction,' says Raymond James

Mar 25, 11:32 AM

Maze Therapeutics falls -33.2%

MAZE

Mar 25, 10:00 AM

Leerink remains bullish on Maze, says Vertex comparison 'apples to oranges'

Mar 25, 9:32 AM

Maze Therapeutics price target raised by $50 at H.C. Wainwright, here's why

MAZE

Mar 25, 9:23 AM

Maze Therapeutics up 15% at $56.43 after Q4 results and MZE829 trial data

MAZE

Mar 25, 8:00 AM

Maze Therapeutics reports Q4 EPS (65c), consensus (78c)

MAZE

Mar 25, 8:00 AM

Maze Therapeutics announces positive topline data from Phase 2 HORIZON Trial

MAZE

Mar 25, 7:59 AM

Block upgraded, Starbucks downgraded: Wall Street's top analyst calls

+12

Mar 18, 9:34 AM

Maze Therapeutics initiated with bullish view at Truist, here's why

MAZE

Mar 17, 4:11 PM

Maze Therapeutics price target raised by $15 at Wedbush, here's why

MAZE

Mar 16, 7:58 AM

Qualcomm downgraded, Rivian upgraded: Wall Street's top analyst calls

+12

Mar 10, 9:34 AM

Maze Therapeutics initiated with bullish view at Mizuho, here's why

MAZE

Mar 10, 4:41 AM

Maze Therapeutics price target raised by $12 at Guggenheim, here's why

MAZE

Mar 4, 7:18 AM

Maze Therapeutics files automatic mixed securities shelf

MAZE

Feb 4, 5:20 PM

Company News

Charts